Lifeward Ltd. (LFWD)
| Market Cap | 9.90M -41.1% |
| Revenue (ttm) | 22.03M -14.1% |
| Net Income | -19.91M |
| EPS | -17.16 |
| Shares Out | 1.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,463 |
| Open | 6.88 |
| Previous Close | 6.74 |
| Day's Range | 6.10 - 6.88 |
| 52-Week Range | 4.14 - 23.04 |
| Beta | 0.14 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+54.32%) |
| Earnings Date | Mar 18, 2026 |
About LFWD
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG ... [Read more]
Financial Performance
In 2025, Lifeward's revenue was $22.03 million, a decrease of -14.14% compared to the previous year's $25.66 million. Losses were -$19.91 million, -31.19% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for LFWD stock is "Strong Buy" and the 12-month stock price target is $10.0.
News
Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results
Advancing t ransformation into a d iversified b iomedical i nnovation c ompany with a c lear p ath to c ash f low p ositiv e Oramed s trategic t ransaction r eceives s hareholder a pproval ; Lifeward ...
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Or...
Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transfo...
Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton
Clinic d ays offered at Shirley Ryan AbilityLab, the #1 ranked rehabilitation hospital for 35 consecutive years , with the goal of a ccelerat ing p ersonal e xoskeleton a doption S treamlined pathway...
Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilities Designed to Restore Function to Stroke Survivors
IP and technology acquisition is expected to be highly accretive and to advance Lifeward's position as a diversified biomedical innovation company Will Expand Lifeward's portfolio beyond lower-limb so...
Lifeward Announces Reverse Share Split
Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company Reverse split initiated as Lifeward enters strategic partnership agreement and ...
Lifeward's ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers
Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intend...
Oramed and Lifeward Announce Strategic Transaction
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while reta...
Lifeward Appoints Bob Marshall as Chairman of the Board
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed t...
Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities
Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval
Humana and UnitedHealthcare, which granted authorization in November, are the two largest Medicare Advantage providers in the U.S., accounting for 47% of all Medicare Advantage enrollees This latest ...
UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Lifeward Ltd. Reports Third Quarter 2025 Financial Results
Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decre...
Lifeward to Report Third Quarter Financial Results on November 14, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
Medicare Advantage claim processed in less than thirty days Additional progress with traditional Medicare claim approvals has accelerated timelines to payment in 2025 MARLBOROUGH, Mass. and YOKNEAM IL...
Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commer...
Lifeward Ltd. Reports Second Quarter 2025 Financial Results
Achieves r ecord n umber of ReWalk s ystems p laced f or Medicare b eneficiaries s ince fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads ...
Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transfor...
Lifeward to Report Second Quarter Financial Results on August 14, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transfor...
Lifeward Expands Distribution Partnership with SportsMed Ltd. to Add Coverage for United Arab Emirates and Entire Gulf Cooperation Council Region
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion
Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer PORTLAND, Maine , July 7,...
Lifeward Announces Closing of $2.6 Million Public Offering
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transfor...
Lifeward Announces Pricing of $2.6 Million Public Offering
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transfor...